Separating technology development from product development

Technology and product development have different talent requirements, timelines, costs, and cultures. We created an efficient model to accommodate these differences. Replay owns and develops core platform technologies, which are developed in a disease area agnostic manner. When we identify a product opportunity that can be addressed by one or more of our platforms, a product company is incorporated with a defined focus in that area.

SYNHSV™

01 / 02

02 / 02

Delivering big DNA

synHSV™ is capable of delivering up to 30x the payload of AAV. We can deliver big genes, genomic genes, and multiple genes, unlocking the promise of polygenic medicine.

HSV: 150kb vs. AVV: 4.8kb — HSV: 150kb vs. AAV: 5kb

Delivering big DNA

83% of genes are too big for AAV

UCELL™

Immune silencing technology

uCell™ is an immune silencing technology that enables iPSCs to be used as a renewable source for cell therapies. This substantially reduces the cost of goods associated with patient- or pooled donor-derived cells, improves product consistency and volume, and enables extensive genome engineering.

DropSynth™

01 / 02

02 / 02

Writing big DNA

DropSynth™ enables the efficient assembly of large libraries of gene-size fragments. These can be used to explore protein sequence space in a manner that is more efficient, cost-effective, and comprehensive than directed evolution.

Writing big DNA

Writing DNA is a million times more expensive than sequencing. Reducing the cost of writing to those of reading will enable the era of genome writing, which has the potential to disrupt multiple industries.

Join Replay

Help us to author the future of genomic medicine

Open positions